Home ETF List About

ETF Holdings Breakdown of BBIO

Stock NameBridgeBio Pharma Inc
TickerBBIO(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS10806X1028
LEI54930028YG89VTY2J114

BBIO institutional holdings

The adjusted close for BBIO on 2025-11-12 was 66.22

The following institutional investment holdings of BBIO have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-12 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 101,066USD 6,692,591 -0.5% 66.22  
2025-11-12 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 38,308 -0.3%USD 2,536,756 -0.9% 66.22  
2025-11-12 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 124,518 0.3%USD 8,245,582 -0.3% 66.22  
2025-11-12 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 124,518 0.3%USD 8,245,582 -0.3% 66.22  
2025-11-12 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 806USD 53,373 -0.5% 66.22  
2025-11-06 IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc)) 3,659USD 229,529 0.1% 62.73 Incorrect share price reported. Should be 66.22 not 62.73. May be due to incorrect reporting of currency . Could be EUR or USD instead 
Total =392,875 USD 26,003,413
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with BBIO

BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $70.00 at HC Wainwright
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target raised by HC Wainwright from $56.00 to $70.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock. A number of other analysts have also recently weighed in on BBIO. Wall Street Zen raised shares of […] - 2025-09-01 03:10:44
BridgeBio Pharma (NASDAQ:BBIO) CFO Sells $2,089,886.76 in Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) CFO Thomas Trimarchi sold 42,237 shares of the stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $49.48, for a total value of $2,089,886.76. Following the sale, the chief financial officer owned 421,081 shares in the company, valued at […] - 2025-08-25 05:07:01
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Swiss National Bank
Swiss National Bank cut its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 1.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 238,000 shares of the company’s stock after selling 2,300 shares during the period. Swiss National Bank’s holdings in BridgeBio Pharma were worth […] - 2025-08-17 05:54:57
Vanguard Group Inc. Cuts Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Vanguard Group Inc. lessened its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 1.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,900,145 shares of the company’s stock after selling 177,770 shares during the quarter. Vanguard Group Inc. owned approximately 0.08% of […] - 2025-08-15 06:12:53
BridgeBio Pharma (NASDAQ:BBIO) Raised to “Hold” at Wall Street Zen
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday. BBIO has been the topic of several other research reports. Wells Fargo & Company lifted their price target on shares of BridgeBio Pharma from $67.00 […] - 2025-08-11 03:58:51
Brokerages Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) PT at $61.50
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have received an average recommendation of “Buy” from the sixteen brokerages that are presently covering the company, Marketbeat reports. Sixteen analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the stock in […] - 2025-07-30 04:24:53
BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated at Truist Financial
Equities researchers at Truist Financial began coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) in a report issued on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $66.00 price target on the stock. Truist Financial’s price target would indicate a potential upside of 44.20% from the company’s current price. […] - 2025-07-23 05:10:52
BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated at Jefferies Financial Group
Equities research analysts at Jefferies Financial Group initiated coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) in a note issued to investors on Monday, Marketbeat reports. The brokerage set a “buy” rating and a $70.00 price target on the stock. Jefferies Financial Group’s price target points to a potential upside of 49.03% […] - 2025-07-16 02:50:48
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $68.00 at Piper Sandler
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price objective boosted by Piper Sandler from $63.00 to $68.00 in a research note published on Monday,Benzinga reports. The firm currently has an overweight rating on the stock. Several other equities research analysts have also recently weighed in on BBIO. Bank of America increased their price objective […] - 2025-07-15 06:21:07
BridgeBio Pharma (NASDAQ:BBIO) Raised to “Outperform” at Oppenheimer
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) was upgraded by stock analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage presently has a $60.00 price objective on the stock. Oppenheimer’s price target would suggest a potential upside of 29.67% […] - 2025-07-11 02:20:48
Principal Financial Group Inc. Has $39.70 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Principal Financial Group Inc. lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 9.3% during the first quarter, HoldingsChannel reports. The fund owned 1,148,292 shares of the company’s stock after purchasing an additional 98,153 shares during the quarter. Principal Financial Group Inc.’s holdings in BridgeBio Pharma were worth $39,696,000 as of its […] - 2025-07-07 05:54:48
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Major Shareholder Sells $154,000,000.00 in Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) major shareholder Global Investors Lp Viking sold 3,500,000 shares of the stock in a transaction on Friday, June 27th. The stock was sold at an average price of $44.00, for a total value of $154,000,000.00. Following the completion of the sale, the insider owned 18,555,375 shares in […] - 2025-07-03 06:00:52
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price objective hoisted by equities researchers at Wells Fargo & Company from $67.00 to $76.00 in a report issued on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 77.65% from the […] - 2025-07-02 02:32:50
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month […] - 2025-06-30 02:46:48
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Frank Mccormick Sells 100,000 Shares
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) Director Frank Mccormick sold 100,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $44.23, for a total value of $4,423,000.00. Following the completion of the transaction, the director now owns 879,979 shares in the […] - 2025-06-29 05:16:56
BridgeBio Pharma (NASDAQ:BBIO) Given New $54.00 Price Target at Bank of America
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price objective raised by equities researchers at Bank of America from $50.00 to $54.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price would suggest a potential upside of 19.68% from the […] - 2025-06-27 02:28:43
BridgeBio Pharma (NASDAQ:BBIO) Given New $56.00 Price Target at HC Wainwright
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target lifted by analysts at HC Wainwright from $53.00 to $56.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 39.69% from the company’s previous […] - 2025-06-11 02:44:48
California State Teachers Retirement System Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
California State Teachers Retirement System lifted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 6.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 115,655 shares of the company’s stock after buying an additional 7,388 shares during the quarter. […] - 2025-06-05 06:18:53
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Mackenzie Financial Corp
Mackenzie Financial Corp increased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,505 shares of the company’s stock after purchasing an additional 592 shares during the […] - 2025-06-05 05:26:59
Dimensional Fund Advisors LP Reduces Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Dimensional Fund Advisors LP cut its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 1.7% during the 4th quarter, Holdings Channel reports. The fund owned 61,665 shares of the company’s stock after selling 1,036 shares during the period. Dimensional Fund Advisors LP’s holdings in BridgeBio Pharma were worth $1,692,000 as of its most […] - 2025-05-15 04:32:47
Analysts Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) Target Price at $57.09
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The […] - 2025-05-14 02:34:53
Envestnet Asset Management Inc. Reduces Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Envestnet Asset Management Inc. reduced its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 18.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 12,926 shares of the company’s stock after selling 2,949 shares during the period. Envestnet Asset Management Inc.’s holdings in BridgeBio Pharma were worth $355,000 at the end of […] - 2025-05-06 04:22:45
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 1-Year High After Better-Than-Expected Earnings
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) shares reached a new 52-week high during trading on Wednesday following a better than expected earnings announcement. The company traded as high as $39.54 and last traded at $38.48, with a volume of 2185851 shares. The stock had previously closed at $36.42. The company reported ($0.88) earnings […] - 2025-05-02 02:09:05
BridgeBio Pharma Target of Unusually High Options Trading (NASDAQ:BBIO)
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) saw some unusual options trading activity on Monday. Stock investors purchased 5,930 put options on the company. This is an increase of 67% compared to the typical volume of 3,542 put options. Wall Street Analysts Forecast Growth A number of equities research analysts have commented on the […] - 2025-04-30 04:24:51
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Legal & General Group Plc
Legal & General Group Plc increased its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 2.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 134,038 shares of the company’s stock after acquiring an additional 3,706 shares […] - 2025-04-23 05:21:00
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Prudential Financial Inc.
Prudential Financial Inc. reduced its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 24.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,429 shares of the company’s stock after selling 3,360 shares during the period. Prudential Financial Inc.’s holdings in BridgeBio […] - 2025-04-11 05:02:57
Vanguard Group Inc. Buys 879,059 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Vanguard Group Inc. raised its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 6.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,077,915 shares of the company’s stock after purchasing an additional 879,059 shares during the period. Vanguard […] - 2025-04-03 04:37:03
KLP Kapitalforvaltning AS Makes New $692,000 Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
KLP Kapitalforvaltning AS bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 25,235 shares of the company’s stock, valued at approximately $692,000. Several other hedge funds also recently made […] - 2025-04-02 05:08:54
BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated at Redburn Atlantic
Equities research analysts at Redburn Atlantic began coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) in a research note issued on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $50.00 price target on the stock. Redburn Atlantic’s target price suggests a potential upside of 51.42% from the company’s current […] - 2025-04-02 02:27:06
American Century Companies Inc. Boosts Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
American Century Companies Inc. lifted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 9.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,015,728 shares of the company’s stock after purchasing an additional 88,882 shares during the quarter. American […] - 2025-03-30 06:42:56

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.